Select Achievements and Experience

Dr. Tracy receives the CRS Distinguished Service Award in July 2013 from CRS President, Prof. I. Tucker (left), and Immediate Past President, Prof. K. Kataoka (right)

• Advanced nine medicines to the clinic, four of which have been commercialized:
  • Nutropin® Depot (protein)
  • Risperdal® Consta (small molecule)
  • Vivitrol® (small molecule)
  • Bydureon® (peptide)

• At Alkermes, Inc., developed the first long-acting protein approved by the FDA and commercialized (Nutropin® Depot)

• Led an international alliance of academic and industry partners while at Alnylam, Inc. that brought new nanotechnology-based RNA products to the clinic and enabled human clinical proof of concept for RNAi and a growing pipeline of RNA-based clinical programs
  • Advanced the first dual targeted RNAi based therapeutic to the clinic

• Fellow, American Institute for Medical and Biological Engineering (AIMBE) www.aimbe.org

• Past President, Controlled Release Society (CRS) (www.controlledreleasesociety.org)

• Adjunct Associate Professor, Department of Pharmaceutical Sciences, Northeastern University

• Education
  • Greater Boston Executive Program, MIT-Sloan School of Management
  • Ph.D., Chemistry, Stanford University
  • M.S., Chemical Engineering, Stanford University (Tau Beta Pi Fellow)
  • B.S., Chemical Engineering, University of Illinois (Summa cum Laude)